BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference
Nov 18, 2022
- The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities
- BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies
- Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, recently presented at Recent Advances in Fermentation Technology (“RAFT”) 14, a conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”), which took place in Orlando, Florida. RAFT provides a platform for academic and industrial scientists to discuss the latest developments in fermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies at the Caribe Royale Orlando on November 8, 2022 (https://ibn.fm/ziT4B).
The RAFT presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nano-sized NanoAbs (aka VHH-antibodies and nanobodies). NanoAbs are a “bio-better” category of monoclonal antibodies (“mAbs”) providing several key advantages vs. currently…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
UK diesel prices top £2 a litre for first time, RAC says
The rise in global oil prices has been pushing up the pump prices of petrol and diesel in the UK.
The Rich People Democrats Aren’t Talking About
As billionaires become a popular political target, a new book urges Washington not to lose sight of a much larger, and quieter, group of wealthy business owners.
Russia’s Latest Propaganda? A.I.-Generated War Songs.
Russians are creating and spreading music glorifying the invasion of Ukraine, using platforms built in the United States.
US jobs market sees sharp slowdown ahead of midterm elections
Unemployment rose slightly as American employers paused hiring with midterm elections just a month away.
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home.
Here’s the latest.
Why UK diesel prices have breached the £2 per litre mark
The average price of a litre of diesel at the pump stands at an all-time high of 200.01p, according to the RAC motoring body.
US Sanctions A7, a Russia Firm That Helps Sidestep Economic Restrictions
The move followed reports detailing how A7, a Moscow firm, uses shell companies around the world to move funds for clients who are themselves subject to sanctions.
English Whisky Gets a Boost from the U.K., and Scots Are Not Amused
A growing cadre of English distillers have won protected status for their liquor. But Scotch producers fear that they’ll lose prestige.
New free repair shop to launch in Oxford
Organisers hope the initiative will attract enough interest to continue on a monthly basis.
Pay Advance Apps May Be Costlier Than Workers Think
The loans tide borrowers over until their next paycheck. The apps offer no-cost options, but most users end up paying high fees, a report finds.
Trump’s Threat to Ban Diesel Exports Sets Off Global Alarms
A reduction in refineries has already driven the price of diesel to record highs, threatening economies. An U.S. export ban would be “tremendous shock and blow.”
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.